5/9/2025

Janusmed sex and gender

Janusmed sex and gender – Pertuzumab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Pertuzumab

Pertuzumab

Class : B

Show all info

Print

Contact us

  1. US National Library of Medicine. Perjeta (pertuzumab). DailyMed [www]. [updated 2018-12-26, cited 2019-05-28].

  2. Perjeta (pertuzumab). Fass.se [www]. [updated 2019-03-28, cited 2019-05-28].

  3. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115-126.

  4. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131.

  5. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.

  6. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. US National Library of Medicine. Perjeta (pertuzumab). DailyMed [www]. [updated 2018-12-26, cited 2019-05-28].
  2. Perjeta (pertuzumab). Fass.se [www]. [updated 2019-03-28, cited 2019-05-28].
  3. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115-126.
  4. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131.
  5. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.
  6. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]